

Ezetimibe / Simvastatin Formulation

Version 5.7 Revision Date: 16.10.2020 SDS Number: 28133-00016 Date of last issue: 23.03.2020
Date of first issue: 04.11.2014

Section 1: Identification

Product name : Ezetimibe / Simvastatin Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address : 30 Hudson Street, 33rd floor
Jersey City, New Jersey, U.S.A 07302

Telephone : 551-430-6000

Emergency telephone number : 215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Section 2: Hazard identification**GHS Classification**

Skin corrosion/irritation : Category 2

Skin sensitisation : Category 1

Specific target organ toxicity - repeated exposure : Category 1 (Liver, muscle, optic nerve, Eye)

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H315 Causes skin irritation.
H317 May cause an allergic skin reaction.
H372 Causes damage to organs (Liver, muscle, optic nerve, Eye) through prolonged or repeated exposure.

Precautionary statements : **Prevention:**
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P272 Contaminated work clothing should not be allowed out of the workplace.
P280 Wear protective gloves.

Response:

Ezetimibe / Simvastatin Formulation

Version 5.7 Revision Date: 16.10.2020 SDS Number: 28133-00016 Date of last issue: 23.03.2020
Date of first issue: 04.11.2014

P302 + P352 IF ON SKIN: Wash with plenty of soap and water.
P314 Get medical advice/ attention if you feel unwell.
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.
P362 Take off contaminated clothing and wash before reuse.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.
May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 10 -< 30
Ezetimibe	163222-33-1	>= 10 -< 30
Simvastatin	79902-63-9	>= 10 -< 30
Magnesium stearate	557-04-0	< 10

Section 4: First-aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : Causes skin irritation.
May cause an allergic skin reaction.
Causes damage to organs through prolonged or repeated exposure.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
5.7	16.10.2020	28133-00016	Date of first issue: 04.11.2014

Section 5: Fire-fighting measures

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Fluorine compounds
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.
- Hazchem Code : Z2
-

Section 6: Accidental release measures

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Ezetimibe / Simvastatin Formulation

Version 5.7 Revision Date: 16.10.2020 SDS Number: 28133-00016 Date of last issue: 23.03.2020
Date of first issue: 04.11.2014

Section 7: Handling and storage

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Contaminated work clothing should not be allowed out of the workplace.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labelled containers.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Section 8: Exposure controls/personal protection**Components with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	WES-TWA	10 mg/m ³	NZ OEL
		TWA	10 mg/m ³	ACGIH
Ezetimibe	163222-33-1	TWA	25 µg/m ³ (OEB 3)	Internal
		Wipe limit	250 µg/100 cm ²	Internal
Simvastatin	79902-63-9	TWA	25 µg/m ³ (OEB 3)	Internal
		Further information: DSEN		
		Wipe limit	250 µg/100 cm ²	Internal
Magnesium stearate	557-04-0	WES-TWA	10 mg/m ³	NZ OEL

Ezetimibe / Simvastatin Formulation

Version 5.7 Revision Date: 16.10.2020 SDS Number: 28133-00016 Date of last issue: 23.03.2020
Date of first issue: 04.11.2014

		TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type
Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.
Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Section 9: Physical and chemical properties

Appearance : powder
Colour : No data available
Odour : No data available
Odour Threshold : No data available
pH : No data available
Melting point/freezing point : No data available

SAFETY DATA SHEET



Ezetimibe / Simvastatin Formulation



Version 5.7 Revision Date: 16.10.2020 SDS Number: 28133-00016 Date of last issue: 23.03.2020
Date of first issue: 04.11.2014

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
5.7	16.10.2020	28133-00016	Date of first issue: 04.11.2014

Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes	:	Inhalation Skin contact Ingestion Eye contact
-----------------	---	--

Acute toxicity

Not classified based on available information.

Components:**Cellulose:**

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg

Ezetimibe:

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg LD50 (Mouse): > 5,000 mg/kg LD50 (Dog): > 3,000 mg/kg
Acute inhalation toxicity	:	Remarks: No data available
Acute dermal toxicity	:	Remarks: No data available
Acute toxicity (other routes of administration)	:	LD50 (Rat): > 2,000 mg/kg Application Route: Intraperitoneal LD50 (Mouse): > 1,000 - < 2,000 mg/kg Application Route: Intraperitoneal

Simvastatin:

Acute oral toxicity	:	LD50 (Rat): 5,000 mg/kg LD50 (Mouse): 3,800 mg/kg
---------------------	---	--

Magnesium stearate:

Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 423 Assessment: The substance or mixture has no acute oral toxicity
---------------------	---	---

Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
5.7	16.10.2020	28133-00016	Date of first issue: 04.11.2014

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation

Causes skin irritation.

Components:**Ezetimibe:**

Species : Rabbit
Result : No skin irritation

Simvastatin:

Species : Rabbit
Remarks : Moderate skin irritation

Magnesium stearate:

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Ezetimibe:**

Species : Rabbit
Result : No eye irritation

Simvastatin:

Species : Rabbit
Remarks : slight irritation

Magnesium stearate:

Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Respiratory or skin sensitisation**Skin sensitisation**

May cause an allergic skin reaction.

Respiratory sensitisation

Not classified based on available information.

Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
5.7	16.10.2020	28133-00016	Date of first issue: 04.11.2014

Components:**Ezetimibe:**

Test Type	:	Maximisation Test
Species	:	Guinea pig
Result	:	negative

Simvastatin:

Assessment	:	Probability or evidence of skin sensitisation in humans
Result	:	positive

Magnesium stearate:

Test Type	:	Maximisation Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Method	:	OECD Test Guideline 406
Result	:	negative
Remarks	:	Based on data from similar materials

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**Cellulose:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
		Result: negative
Genotoxicity in vivo	:	Test Type: In vitro mammalian cell gene mutation test
		Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
		Species: Mouse
		Application Route: Ingestion
		Result: negative

Ezetimibe:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
		Metabolic activation: with and without metabolic activation
Genotoxicity in vivo	:	Result: negative
		Test Type: Chromosomal aberration
Genotoxicity in vivo	:	Test system: Human lymphocytes
		Result: negative
		Test Type: Micronucleus test
		Species: Mouse
Genotoxicity in vivo	:	Cell type: Bone marrow
		Application Route: Oral
		Result: negative

Ezetimibe / Simvastatin Formulation

Version 5.7 Revision Date: 16.10.2020 SDS Number: 28133-00016 Date of last issue: 23.03.2020
Date of first issue: 04.11.2014

Simvastatin:

- Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
- Test Type: Alkaline elution assay
Result: negative
- Test Type: Chromosomal aberration
Result: negative
- Test Type: In vitro mammalian cell gene mutation test
Result: negative
- Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative
- Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Magnesium stearate:

- Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials
- Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials
- Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:**Cellulose:**

- Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Ezetimibe:

- Species : Rat, female
Application Route : oral (feed)
Exposure time : 104 weeks
Result : negative

Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
5.7	16.10.2020	28133-00016	Date of first issue: 04.11.2014

Species : Rat, male
 Application Route : oral (feed)
 Exposure time : 104 weeks
 Result : negative

Species : Mouse
 Application Route : oral (feed)
 Exposure time : 104 weeks
 Result : negative

Simvastatin:

Species : Mouse
 Application Route : Oral
 Exposure time : < 92 weeks
 Target Organs : Harderian gland
 Tumor Type : Liver, Lungs
 Remarks : The significance of these findings for humans is not certain.

Species : Rat
 Application Route : Oral
 Exposure time : 2 Years
 Tumor Type : Liver, Thyroid
 Remarks : The significance of these findings for humans is not certain.

Reproductive toxicity

Not classified based on available information.

Components:**Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study
 Species: Rat
 Application Route: Ingestion
 Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development
 Species: Rat
 Application Route: Ingestion
 Result: negative

Ezetimibe:

Effects on fertility : Test Type: Fertility/early embryonic development
 Species: Rat, male and female
 Fertility: NOAEL: > 1,000 mg/kg body weight
 Result: No effects on fertility, No fetotoxicity

Effects on foetal development : Test Type: Development
 Species: Rat
 Application Route: Oral
 Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight
 Result: No adverse effects

Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
5.7	16.10.2020	28133-00016	Date of first issue: 04.11.2014

Test Type: Development
 Species: Rabbit
 Application Route: Oral
 Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight
 Result: No adverse effects

Simvastatin:

Effects on fertility : Test Type: Fertility
 Species: Rat, male
 Application Route: Oral
 Fertility: LOAEL: 25 mg/kg body weight

Effects on foetal development : Test Type: Embryo-foetal development
 Species: Rat
 Application Route: Oral
 Embryo-foetal toxicity: NOAEL: 25 mg/kg body weight
 Result: No teratogenic effects, No adverse effects

Test Type: Embryo-foetal development
 Species: Rabbit
 Application Route: Oral
 Embryo-foetal toxicity: NOAEL: 10 mg/kg body weight
 Result: No teratogenic effects, No adverse effects

Test Type: Embryo-foetal development
 Species: Rat
 Application Route: Oral
 Embryo-foetal toxicity: LOAEL: 60 mg/kg body weight
 Result: Teratogenic potential
 Remarks: Based on data from similar materials

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
 Species: Rat
 Application Route: Ingestion
 Method: OECD Test Guideline 422
 Result: negative
 Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development
 Species: Rat
 Application Route: Ingestion
 Result: negative
 Remarks: Based on data from similar materials

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs (Liver, muscle, optic nerve, Eye) through prolonged or repeated exposure.

Ezetimibe / Simvastatin Formulation

Version 5.7 Revision Date: 16.10.2020 SDS Number: 28133-00016 Date of last issue: 23.03.2020
 Date of first issue: 04.11.2014

Components:**Simvastatin:**

Target Organs : Liver, muscle, optic nerve, Eye
 Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Cellulose:**

Species : Rat
 NOAEL : >= 9,000 mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days

Ezetimibe:

Species : Dog
 NOAEL : 1,000 mg/kg
 Application Route : Oral
 Exposure time : 90 d
 Remarks : No significant adverse effects were reported

Species : Rat
 NOAEL : 1,500 mg/kg
 Application Route : Oral
 Exposure time : 90 d
 Remarks : No significant adverse effects were reported

Species : Mouse
 NOAEL : 500 mg/kg
 Application Route : Oral
 Exposure time : 90 d
 Remarks : No significant adverse effects were reported

Species : Dog
 NOAEL : 300 mg/kg
 Application Route : Oral
 Exposure time : 1 yr
 Remarks : No significant adverse effects were reported

Simvastatin:

Species : Rat
 NOAEL : 5 mg/kg
 LOAEL : 30 mg/kg
 Application Route : Oral
 Exposure time : 14 - 104 Weeks
 Target Organs : Liver, Testis, Musculo-skeletal system, Eye

Species : Dog
 LOAEL : 10 mg/kg
 Application Route : Oral

Ezetimibe / Simvastatin Formulation

Version 5.7 Revision Date: 16.10.2020 SDS Number: 28133-00016 Date of last issue: 23.03.2020
 Date of first issue: 04.11.2014

Exposure time : 14 - 104 Weeks
 Target Organs : Liver, Testis, Eye

Species : Rabbit
 NOAEL : 30 mg/kg
 LOAEL : 50 mg/kg
 Application Route : Oral
 Target Organs : Liver, Kidney

Magnesium stearate:

Species : Rat
 NOAEL : > 100 mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days
 Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Components:**Ezetimibe:**

Not applicable

Experience with human exposure**Components:****Ezetimibe:**

Ingestion : Symptoms: Headache, Nausea, Vomiting, Diarrhoea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain

Simvastatin:

Skin contact : Remarks: May produce an allergic reaction.
 Ingestion : Target Organs: Liver
 Symptoms: upper respiratory tract infection, Headache, Abdominal pain, constipation, Nausea
 Target Organs: Musculo-skeletal system

Section 12: Ecological information**Ecotoxicity****Components:****Cellulose:**

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
 Exposure time: 48 h
 Remarks: Based on data from similar materials

Ezetimibe:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 0.125 mg/l

Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
5.7	16.10.2020	28133-00016	Date of first issue: 04.11.2014

- Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 4 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.317 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility
- NOEC (Pseudokirchneriella subcapitata (green algae)): 0.317 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility
- Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.051 mg/l
Exposure time: 33 d
Method: OECD Test Guideline 210
- NOEC (Cyprinodon variegatus (sheepshead minnow)): 4 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.282 mg/l
Exposure time: 21 d
Remarks: No toxicity at the limit of solubility
- Toxicity to microorganisms : EC50: > 4.4 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility
- NOEC: 4.4 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility
- Simvastatin:**
- Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 2.91 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 3.5 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
5.7	16.10.2020	28133-00016	Date of first issue: 04.11.2014

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 25 mg/l
Exposure time: 96 h

NOEC (Pseudokirchneriella subcapitata (green algae)): 25 mg/l
Exposure time: 96 h

Toxicity to microorganisms : EC50: > 30 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 21 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Method: Directive 67/548/EEC, Annex V, C.2.
Remarks: Based on data from similar materials
No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Ezetimibe / Simvastatin Formulation

Version 5.7 Revision Date: 16.10.2020 SDS Number: 28133-00016 Date of last issue: 23.03.2020
Date of first issue: 04.11.2014

Persistence and degradability**Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

Ezetimibe:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 6.8 %
Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(4.5 d)
Method: OECD Test Guideline 111

Simvastatin:

Biodegradability : Result: rapidly degradable

Stability in water : Hydrolysis: 50 %(3.2 d)

Magnesium stearate:

Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials

Bioaccumulative potential**Components:****Ezetimibe:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 173
Exposure time: 97 d
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.36

Simvastatin:

Partition coefficient: n-octanol/water : log Pow: > 4.07

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil**Components:****Ezetimibe:**

Distribution among environmental compartments : log Koc: 4.35
Method: OECD Test Guideline 106

Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
5.7	16.10.2020	28133-00016	Date of first issue: 04.11.2014

Other adverse effects

No data available

Section 13: Disposal considerations**Disposal methods**

Waste from residues	:	Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

Section 14: Transport information**International Regulations****UNRTDG**

UN number	:	UN 3077
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Simvastatin)
Class	:	9
Packing group	:	III
Labels	:	9

IATA-DGR

UN/ID No.	:	UN 3077
Proper shipping name	:	Environmentally hazardous substance, solid, n.o.s. (Ezetimibe, Simvastatin)
Class	:	9
Packing group	:	III
Labels	:	Miscellaneous
Packing instruction (cargo aircraft)	:	956
Packing instruction (passenger aircraft)	:	956
Environmentally hazardous	:	yes

IMDG-Code

UN number	:	UN 3077
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Simvastatin)
Class	:	9
Packing group	:	III
Labels	:	9
EmS Code	:	F-A, S-F
Marine pollutant	:	yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**NZS 5433**

UN number	:	UN 3077
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
5.7	16.10.2020	28133-00016	Date of first issue: 04.11.2014

	N.O.S. (Ezetimibe, Simvastatin)
Class	: 9
Packing group	: III
Labels	: 9
Hazchem Code	: 2Z

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

Section 15: Regulatory information**Safety, health and environmental regulations/legislation specific for the substance or mixture****HSNO Approval Number**

HSR100425 Pharmaceutical Active Ingredients Group Standard 2017

HSW Controls

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

Section 16: Other information**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH	: USA. ACGIH Threshold Limit Values (TLV)
NZ OEL	: New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / TWA	: 8-hour, time-weighted average
NZ OEL / WES-TWA	: Workplace Exposure Standard - Time Weighted average

Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
5.7	16.10.2020	28133-00016	Date of first issue: 04.11.2014

AIIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN